KR20030028234A - Extracts of buckwheat and/or buchwheat chaff with anti-inflammatory effects and composition comprising of the same - Google Patents
Extracts of buckwheat and/or buchwheat chaff with anti-inflammatory effects and composition comprising of the same Download PDFInfo
- Publication number
- KR20030028234A KR20030028234A KR1020010060247A KR20010060247A KR20030028234A KR 20030028234 A KR20030028234 A KR 20030028234A KR 1020010060247 A KR1020010060247 A KR 1020010060247A KR 20010060247 A KR20010060247 A KR 20010060247A KR 20030028234 A KR20030028234 A KR 20030028234A
- Authority
- KR
- South Korea
- Prior art keywords
- buckwheat
- extract
- solvent
- inflammatory
- inflammation
- Prior art date
Links
- 241000219051 Fagopyrum Species 0.000 title claims abstract description 115
- 235000009419 Fagopyrum esculentum Nutrition 0.000 title claims abstract description 115
- 239000000284 extract Substances 0.000 title claims abstract description 109
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 31
- 239000010903 husk Substances 0.000 claims abstract description 35
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 30
- 239000002904 solvent Substances 0.000 claims abstract description 30
- 239000000463 material Substances 0.000 claims abstract description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000007864 aqueous solution Substances 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 17
- 239000000126 substance Substances 0.000 claims description 15
- 235000013361 beverage Nutrition 0.000 claims description 7
- 235000021067 refined food Nutrition 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 235000013376 functional food Nutrition 0.000 claims description 6
- 239000000654 additive Substances 0.000 claims description 5
- 238000005377 adsorption chromatography Methods 0.000 claims description 5
- 239000002778 food additive Substances 0.000 claims description 5
- 235000013373 food additive Nutrition 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 4
- 235000012149 noodles Nutrition 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 235000020510 functional beverage Nutrition 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 abstract description 24
- 230000004054 inflammatory process Effects 0.000 abstract description 23
- 239000002158 endotoxin Substances 0.000 abstract description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 4
- 230000001939 inductive effect Effects 0.000 abstract description 2
- 238000004587 chromatography analysis Methods 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 19
- 235000013305 food Nutrition 0.000 description 16
- 230000002401 inhibitory effect Effects 0.000 description 14
- 229920006008 lipopolysaccharide Polymers 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
- 208000005141 Otitis Diseases 0.000 description 7
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 6
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229940030275 epigallocatechin gallate Drugs 0.000 description 6
- 238000001179 sorption measurement Methods 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 244000269722 Thea sinensis Species 0.000 description 3
- 206010000269 abscess Diseases 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- NNDIXBJHNLFJJP-UHFFFAOYSA-N 20-Hydroxyeicosatetraenoic acid Chemical compound OCCCCCC=CCC=CCC=CCC=CCCCC(O)=O NNDIXBJHNLFJJP-UHFFFAOYSA-N 0.000 description 2
- TYJOQICPGZGYDT-UHFFFAOYSA-N 4-methylsulfonylbenzenesulfonyl chloride Chemical compound CS(=O)(=O)C1=CC=C(S(Cl)(=O)=O)C=C1 TYJOQICPGZGYDT-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 208000038016 acute inflammation Diseases 0.000 description 2
- 230000006022 acute inflammation Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000009569 green tea Nutrition 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000000147 hypnotic effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 235000021404 traditional food Nutrition 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 229960004175 xylazine hydrochloride Drugs 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- GWNVDXQDILPJIG-SHSCPDMUSA-N Leukotriene C4 Natural products CCCCCC=C/CC=C/C=C/C=C/C(SCC(NC(=O)CCC(N)C(=O)O)C(=O)NCC(=O)O)C(O)CCCC(=O)O GWNVDXQDILPJIG-SHSCPDMUSA-N 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241001467018 Typhis Species 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000002790 anti-mutagenic effect Effects 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000016213 coffee Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- VNYSSYRCGWBHLG-AMOLWHMGSA-M leukotriene B4(1-) Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC([O-])=O VNYSSYRCGWBHLG-AMOLWHMGSA-M 0.000 description 1
- GWNVDXQDILPJIG-NXOLIXFESA-N leukotriene C4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-NXOLIXFESA-N 0.000 description 1
- 235000020094 liqueur Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000021057 semi-liquid food Nutrition 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/109—Types of pasta, e.g. macaroni or noodles
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
Abstract
Description
본 발명은 항염증 활성을 가지는, 메밀, 메밀껍질, 및 이들의 혼합물로 이루어진 군에서 선택된 물질의 추출물 및 이를 유효성분으로 포함하는 항염증 조성물에 관한 것이다.The present invention relates to an anti-inflammatory composition comprising an extract of a substance selected from the group consisting of buckwheat, buckwheat bark, and mixtures thereof and having an anti-inflammatory activity as an active ingredient.
우리나라의 전통식품 중 하나인 메밀은 단백질과 필수아미노산, 나이아신, 각종 비타민류, 칼슘, 철분 등이 풍부한 영양 생화학적 가치가 높은 것으로, 메밀국수, 메밀묵, 메밀부침, 메밀당수, 및 메밀산자 등 다양한 식품과 조리법으로 이용되고 있다(유태종, 음식궁합, 1996). 이러한 메밀을 이용한 전통식품은 민간요법으로 고혈압, 당뇨병, 비만 등의 예방 및 치료의 효과가 있는 것으로 알려져 있다(정동효 외, 식품의 생리활성, 선진문화사, 1998). 한편, 종래 메밀 추출물의 생리활성에 관한 연구로서는, 혈압 조절 효능(최면, 한국영양식량학회지, 20:300-305, 1991), 당뇨병 치료 효능(최면, 한국영양식량학회지, 21:478-483, 1992), 항돌연변이 효능(함승시, 메밀잎 에탄올 추출물의 항돌연변이원성에 관한 연구보고서, 32:1141-1148, 1994), 신장개선에 대한 효능(Yokozawa,Biosci. Biotechnol. Biochem., 65:396-400. 2001)이 보고되었을 뿐, 그밖에 다른 생리활성에 대한 연구 보고는 전무하다. 특히, 여러 식품으로 이용되어 온 메밀 및 메밀껍질 분획물들이 세균의 내독소 및 외부 염증 유발물질에 의해 발생하는 염증에 대한 억제 효능을 갖는지에 대한 연구는 현재까지 전혀 보고된 바가 없다.Buckwheat, one of the traditional foods in Korea, has high nutritional biochemical value, rich in protein, essential amino acids, niacin, various vitamins, calcium, iron, and so on. It is used in food and recipes (Jewish, food compatibility, 1996). Traditional foods using buckwheat are known to have the effect of preventing and treating hypertension, diabetes mellitus, obesity, etc. as folk remedies (Jung Dong-hyo, et al., Food History, Advanced Culture History, 1998). On the other hand, studies on the physiological activity of conventional buckwheat extract, blood pressure control efficacy (hypnosis, Korean Journal of Nutrition and Nutrition, 20: 300-305, 1991), diabetes treatment efficacy (hypnosis, Korean Journal of Nutrition and Nutrition, 21: 478-483, 1992), antimutagenic efficacy (in seungseung, research report on antimutagenicity of buckwheat leaf ethanol extract, 32: 1141-1148, 1994), efficacy on kidney improvement (Yokozawa, Biosci. Biotechnol. Biochem. , 65: 396- 400. 2001), there are no other research reports on other biological activities. In particular, no studies have been conducted on whether buckwheat and buckwheat husk fractions that have been used in various foods have inhibitory effects on inflammation caused by bacterial endotoxins and external inflammatory agents.
염증이란 세균 유래의 농양으로서 조직에 침입하여 증식된 화농균류를 백혈구가 왕성히 탐식하여, 그 결과 생기는 백혈구의 사해, 균에 의해 장해를 받은 조직, 세포파괴물 등이 조직내 융해하여 농이 축적된 곳의 병리적 상태를 말하며, 소염작용이라 함은 침입균의 증식을 항균제 등에 의하여 억제한다든지, 혹은 농양중에 축적된 이물을 탐식하는 마크로파지(macrophage)를 활성화하여 그것들을 소화, 배설하는 기능을 높여서 농양의 치료과정이 촉진되는 것을 말한다. 일반적으로 염증 반응은 생체의 세포나 조직에 어떠한 기질적 변화를 가져오는 침습이 가해질 때 그 손상부위를 수복 재생하려고 하는 생체의 방어 반응과정이다. 따라서, 이러한 일련의 반응에는 국소의 혈관, 체액의 각종 조직세포, 면역관여 세포 등이 포함된다고 한다.Inflammation is a bacterium-derived abscess that actively infiltrate tissues with purulent fungi that white blood cells devour, resulting in the death of white blood cells, tissues damaged by bacteria, and cell debris, which accumulate in the tissues. The pathological state of the place, and the anti-inflammatory effect is to inhibit the growth of invading bacteria by antibacterial agents, or to activate the macrophage (macrophage) that phages the foreign matter accumulated in the abscesses to enhance the ability to digest and excrete them Abscess is the process of treatment. In general, an inflammatory response is a defense process of a living body that attempts to repair and repair the damaged area when an invasion that causes some organic change in a cell or tissue of the living body is applied. Therefore, such a series of reactions include local blood vessels, various tissue cells of body fluids, immune-involved cells, and the like.
현재까지 항염증 작용물질들은 급성염증에서 손상된 조직의 세포나 염증에 관여하는 세포 또는 주화인자에 의해 유주된 백혈구의 세포막으로부터 물리화학적 및 생리적 자극에 의해 활성화된 프로스타글란딘류의 생합성을 억제하는 약물들이었다(Moyazawa, K and Mikami, T., Japan J. Pharmacol., 38, 199, 1985). 그러나 이런 약물들은 급성염증에서의 증상들에 대해서는 치료효과를 가지고 있지만 류마티스 관절염과 같은 만성염증에서는 1차적인 염증현상만을 완화할 뿐이며, 면역학적 치료효과는 기대할 수 없다고 보고되고 있다. 한편 근래에는 아라키돈 산 (arachidonic acid)이 리폭시게네이즈(lipoxygenase)에 의해 생성되는 물질인 히드록시에이코사테트라에노익 산(HETE; hydroxyeicosatetraenoic acid), 류코트리엔 B4, 류코트리엔 C4 등에 관하여 연구가 활발하게 진행되고 있으며, 이는 만성염증에서 어느 정도 효과를 보이고 있다고 한다(Huskisson, E.D. et al., Inflamma- tion, Mechanism and Treatment, MTP, Lancaster, England, p.55, 1980).To date, anti-inflammatory agents have been shown to inhibit the biosynthesis of prostaglandins activated by physicochemical and physiological stimuli from the cell membranes of damaged tissues or leukocytes inoculated by chemotactic factors in acute inflammation. (Moyazawa, K and Mikami, T., Japan J. Pharmacol., 38, 199, 1985). However, these drugs have a therapeutic effect on the symptoms of acute inflammation, but in chronic inflammation such as rheumatoid arthritis, only the primary inflammation is reported, and immunological therapeutic effects are not expected. Recently, researches on arachidonic acid have been actively conducted on hydroxyeicosatetraenoic acid (HETE), leukotriene B4, and leukotriene C4, which are substances produced by lipoxygenase. This has been shown to have some effect on chronic inflammation (Huskisson, ED et al., Inflammation, Mechanism and Treatment, MTP, Lancaster, England, p.55, 1980).
따라서 천연식물 추출물을 포함하여 별도의 정제 과정 없이 안전하게 섭취할 수 있으며, 염증을 억제할 수 있고, 용이하게 식품에 이용할 수 있는 물질에 대한 연구가 필요한 실정이다.Therefore, it is necessary to study the substances that can be safely ingested without additional purification process, including natural plant extracts, can inhibit inflammation, and can be easily used in food.
본 발명은 항염증 활성을 가지는, 메밀, 메밀껍질, 및 이들의 혼합물로 이루어진 군에서 선택된 물질의 추출물을 제공하는 것을 목적으로 한다.It is an object of the present invention to provide an extract of a substance selected from the group consisting of buckwheat, buckwheat husk, and mixtures thereof having anti-inflammatory activity.
본 발명의 또다른 목적은 항염증 활성을 가지는, 메밀, 메밀껍질, 및 이들의 혼합물로 이루어진 군에서 선택된 물질의 용매추출물을 제공하는 것이다.It is another object of the present invention to provide a solvent extract of a material selected from the group consisting of buckwheat, buckwheat husk, and mixtures thereof having anti-inflammatory activity.
본 발명의 또다른 목적은 항염증 활성을 가지는, 메밀, 메밀껍질, 및 이들의 혼합물로 이루어진 군에서 선택된 물질의 용매추출물에 대해 흡착 크로마토그래피를 수행하여 얻어진 분획추출물을 제공하는 것이다.It is another object of the present invention to provide a fraction extract obtained by performing adsorption chromatography on a solvent extract of a material selected from the group consisting of buckwheat, buckwheat bark, and mixtures thereof having anti-inflammatory activity.
본 발명의 또다른 목적은 상기 항염증 활성을 가지는, 메밀, 메밀껍질, 및 이들의 혼합물로 이루어진 군에서 선택된 물질의 추출물을 유효성분으로 포함하는 약제, 가공식품, 기능성 식품, 식품첨가제, 기능성 음료, 또는 음료첨가제를 제공하는 것이다.Still another object of the present invention is an agent, a processed food, a functional food, a food additive, a functional beverage comprising an extract of a material selected from the group consisting of buckwheat, buckwheat bark, and mixtures thereof having the anti-inflammatory activity as an active ingredient. Or to provide a beverage additive.
도 1은 본 발명에 따른 메밀 분획추출물이 리포폴리사카라이드(LPS; lipopolysaccharide)에 의해 유발된 쥐 치사율을 저해하는 효능을 측정한 것이다.1 is a measure of the effect of the buckwheat fraction extract according to the present invention inhibits rat mortality caused by lipopolysaccharide (LPS; lipopolysaccharide).
도 2는 본 발명에 따른 메밀껍질 분획추출물이 리포폴리사카라이드에 의해 유발된 쥐 치사율을 저해하는 효능을 측정한 것이다.Figure 2 is a measure of the efficacy of buckwheat shell fraction extract according to the present invention inhibits rat mortality caused by lipopolysaccharide.
도 3은 본 발명에 따른 메밀 분획추출물이 티피에이(TPA; 12-ο-tetradecanoylphorbol-13-acetate)에 의해 유발된 쥐의 귀 염증을 억제하는 정도를 측정한 것이다.Figure 3 measures the extent to which the buckwheat fraction extract according to the present invention inhibits ear inflammation in rats induced by TPA (12- ο- tetradecanoylphorbol-13-acetate).
도 4는 본 발명에 따른 메밀껍질 분획추출물이 티피에이에 의해 유발된 쥐의 귀 염증을 억제하는 효능을 측정한 것이다.Figure 4 is a buckwheat shell fraction extract according to the present invention is to measure the efficacy of inhibiting ear inflammation of the rat induced by T.P.
도 5는 본 발명에 따른 메밀 분획추출물, 메밀껍질 분획추출물, 및 에피갈로카테킨갈레이트(EGCG; epigallocatechingallate)가 티피에이에 의해 유발된 쥐의 귀 염증을 억제하는 효능을 측정하여 비교한 것이다.Figure 5 is a comparison of the buckwheat fraction extract, buckwheat shell fraction extract, and epigallocatechin gallate (EGCG; epigallocatechingallate) according to the present invention to determine the efficacy of inhibiting ear inflammation in rats induced by T.P.
상기 목적을 달성하기 위하여, 본 발명은 항염증 활성을 가지는, 메밀, 메밀껍질, 및 이들의 혼합물로 이루어진 군에서 선택된 물질의 추출물, 및 이를 유효성분으로 포함하는 약제, 가공식품, 기능성 식품, 식품첨가제, 기능성 음료, 또는 음료첨가제를 제공한다.In order to achieve the above object, the present invention has an anti-inflammatory activity, buckwheat, buckwheat bark, and an extract of a substance selected from the group consisting of a mixture thereof, and pharmaceutical, processed food, functional food, food comprising the same as an active ingredient Provided are additives, functional beverages, or beverage additives.
이하 본 발명을 상세하게 설명한다.Hereinafter, the present invention will be described in detail.
본 발명자들은 메밀, 및 메밀껍질의 추출물이 동물실험에서 세균의 내독소 및 염증 유발 물질들에 의해 발생되는 염증 저해 효능이 우수함을 확인하고, 이를 토대로 본 발명을 완성하게 되었다.The inventors have confirmed that the extract of buckwheat and buckwheat husk is excellent in inhibiting inflammation caused by bacterial endotoxin and inflammation-causing substances in animal experiments, and completed the present invention based on this.
본 발명은 항염증 활성을 가지는, 메밀, 메밀껍질, 및 이들의 혼합물로 이루어진 군에서 선택된 물질의 추출물에 관한 것이다. 또한, 상기 추출물은 용매 추출물일 수 있으며, 바람직하게는 메밀, 메밀껍질, 및 이들의 혼합물로 이루어진 군에서 선택된 물질의 용매추출물에 흡착 크로마토그래피를 수행하여 얻어진 분획추출물이다.The present invention relates to extracts of substances selected from the group consisting of buckwheat, buckwheat husk, and mixtures thereof, having anti-inflammatory activity. In addition, the extract may be a solvent extract, preferably a fraction extract obtained by performing adsorption chromatography on a solvent extract of a material selected from the group consisting of buckwheat, buckwheat husk, and mixtures thereof.
상기 용매추출물과 관련하여, 본 기술분야의 전문가에게 알져진 통상의 용매추출법을 메밀, 메밀껍질, 및 이들의 혼합물로 이루어진 군에서 선택된 물질을 추출하기 위해서 사용할 수 있다. 바람직하게는 용매가 에탄올, 아세톤, 또는 메탄올인 것이며, 식품에 적용하기 위해서는 용매가 에탄올인 것이 더욱 바람직하나, 이에 한정되지 않는다. 또한 상기 용매추출물은 에탄올, 아세톤, 또는 메탄올 등의 용매를 20 내지 80 %의 물을 포함하는 것이 바람직하며, 더욱 바람직하게는 50 %의 용매를 포함하는 수용액이다.In relation to the solvent extract, conventional solvent extraction methods known to those skilled in the art can be used to extract materials selected from the group consisting of buckwheat, buckwheat husk, and mixtures thereof. Preferably, the solvent is ethanol, acetone, or methanol, and in order to apply to food, the solvent is more preferably ethanol, but is not limited thereto. In addition, the solvent extract preferably contains 20 to 80% of a solvent such as ethanol, acetone, or methanol, more preferably an aqueous solution containing 50% of a solvent.
상기 분획추출물과 관련하여, 상기 용매추출물을 흡착 칼럼에 로딩하여 용매로 용출하여 분획추출물을 얻을 수 있으며, 본 기술분야의 전문가에게 알려진 통상의 흡착 크로마토그래피를 모두 적용할 수 있다. 예컨대, 흡착 칼럼은 스틸렌계 다공성 흡착수지, 소수성 충진제인 XAD-4 또는 HP-20을 사용할 수 있다. 본 발명의 일례에서, 상기 용매추출물을 흡착 칼럼에 충진시킨 후, 10 내지 30 % 에탄올 용액으로 세척하고, 40 내지 80 % 에탄올로 용매분획하여 제조할 수 있다. 더욱 바람직하게는 본 발명의 분획추출물은 20 % 에탄올로 세척하고, 40 % 에탄올로 용매분획하여 제조할 수 있다.In relation to the fraction extract, the solvent extract may be loaded on an adsorption column and eluted with a solvent to obtain a fraction extract, and all of the usual adsorption chromatography known to those skilled in the art may be applied. For example, the adsorption column may use a styrene-based porous adsorption resin, a hydrophobic filler XAD-4 or HP-20. In one example of the present invention, after filling the solvent extract in the adsorption column, it can be prepared by washing with 10 to 30% ethanol solution, solvent fractionation with 40 to 80% ethanol. More preferably, the fraction extract of the present invention can be prepared by washing with 20% ethanol and solvent fractionation with 40% ethanol.
또한 본 발명은 상기 항염증 활성을 가지는, 메밀, 메밀껍질, 및 이들의 혼합물로 이루어진 군에서 선택된 물질의 추출물을 유효성분으로 포함하는 항염증 조성물을 제공하는 것이다. 상기 항염증 조성물은 약제, 가공식품, 기능성 식품, 식품첨가제, 기능성 음료, 또는 음료첨가제 등으로 사용될 수 있다.In another aspect, the present invention provides an anti-inflammatory composition comprising an extract of a material selected from the group consisting of buckwheat, buckwheat bark, and mixtures thereof having the anti-inflammatory activity as an active ingredient. The anti-inflammatory composition may be used as a drug, processed food, functional food, food additives, functional drinks, or beverage additives.
상기 메밀, 메밀껍질, 및 이들의 혼합물로 이루어진 군에서 선택된 물질의 추출물은 조성물 전체에 대하여 0.01 내지 10 중량%로 포함되는 것이 바람직하다. 또한 상기 추출물을 유효성분으로 포함하는 조성물은 경구투여 하는 것이 바람직하다.The extract of the material selected from the group consisting of buckwheat, buckwheat bark, and mixtures thereof is preferably included in an amount of 0.01 to 10% by weight based on the total composition. In addition, the composition containing the extract as an active ingredient is preferably administered orally.
상기 메밀, 메밀껍질, 및 이들의 혼합물로 이루어진 군에서 선택된 물질의 추출물이 염증 치료용 약제로 사용되기 위해서는 약제학적 분야에서 공지의 방법에 의하여 제조될 수 있으며, 그 자체 또는 약제학적으로 허용되는 담체(carrier), 부형제(forming agent), 희석제(diluent) 등과 혼합하여 분말, 과립, 정제, 캡슐제, 또는 주사제 등의 제형으로 제조하여 사용될 수 있다. 구체적으로 상기 약제 염증성 질환 등에 사용될 수 있고, 바람직하게는 세균의 내독소와 외부 염증 유발 물질 등에 의해 발생하는 염증에 효과적인 치료제로 사용될 수 있다.The extract of the material selected from the group consisting of the buckwheat, buckwheat bark, and mixtures thereof may be prepared by a known method in the pharmaceutical field, to be used as a medicament for treating inflammation, or a pharmaceutically acceptable carrier It may be mixed with a carrier, a forming agent, a diluent, and the like to prepare a powder, granule, tablet, capsule, or injection formulation. Specifically, the drug may be used for inflammatory diseases and the like, and may be preferably used as an effective therapeutic agent for inflammation caused by bacterial endotoxins and external inflammation causing substances.
또한 상기 항염증 활성을 가지는, 메밀, 메밀껍질, 및 이들의 혼합물로 이루어진 군에서 선택된 물질의 추출물을 유효성분으로 포함하는 가공식품, 기능성 식품, 식품첨가제, 기능성 음식, 또는 음식첨가제로 사용될 경우, 그대로, 또는 종래 식품에 사용되던 각종 성분과 혼합하여 식품으로 제조할 수 있다. 제조되는 음식물의 형태로서는 고형식품, 크림상, 또는 잼상의 반(半)유동식품, 겔상식품, 음료 등 여러 식품형태로 제조할 수 있으며, 캅셀제, 과립제, 정제, 드링크제 등의 형태나, 상용되고 있는 임의의 기재를 사용하여 청량음료, 쥬스, 커피, 홍차, 리큐르, 우유, 유청음료, 유산균음료, 사탕, 츄잉검, 초콜렛, 구미, 요구르트, 아이스크림, 푸딩, 물양갱 등으로 제조할 수 있다.In addition, when used as processed foods, functional foods, food additives, functional foods, or food additives containing an extract of a substance selected from the group consisting of buckwheat, buckwheat bark, and mixtures thereof having the anti-inflammatory activity as an active ingredient, It may be prepared as a food as it is, or mixed with various components used in the conventional food. The foods to be prepared can be prepared in various food forms such as solid foods, creamy or jam-like semi-liquid foods, gel foods, and beverages, and are commonly used in the form of capsules, granules, tablets, drinks, and the like. Any substrate can be used to prepare soft drinks, juices, coffee, tea, liqueurs, milk, whey beverages, lactic acid bacteria beverages, candies, chewing gum, chocolate, gummi, yogurt, ice cream, puddings, water yolks and the like.
본 발명의 항염증 활성을 가지는 메밀, 메밀껍질, 및 이들의 혼합물로 이루어진 군에서 선택된 물질의 추출물을 유효성분으로 포함하는 가공식품으로 국수를 제조할 수 있으며, 소맥분, 물, 식염을 혼합하고 반죽하여 제조된 통상의 국수에 있어서, 국수 전체 중량부에 대하여 본 발명의 메밀 분획추출물 또는 메밀껍질 분획추출물을 1 내지 70 중량부로 가하여 제조할 수 있다.Noodles can be prepared as a processed food comprising an extract of a substance selected from the group consisting of buckwheat, buckwheat bark, and mixtures thereof having an anti-inflammatory activity of the present invention as an active ingredient, mixing flour and water, salt, and kneading In a conventional noodle prepared by adding the buckwheat fraction extract or buckwheat husk fraction extract of the present invention to 1 part by weight to 70 parts by weight based on the total weight of noodles.
따라서, 본 발명에 의한 메밀 및 메밀껍질 추출물이 항염증 효능을 갖는지를 확인하기 위해서, 세균의 내독소 및 티피에이에 의해 유발되는 염증에 대한 효과를 조사하였다.Therefore, in order to confirm that the buckwheat and buckwheat bark extract according to the present invention has anti-inflammatory effects, the effect on bacterial endotoxin and inflammation induced by TP was investigated.
도 1 및 도 2에서 알 수 있는 바와 같이, 메밀 분획추출물과 메밀껍질 분획추출물을 쥐에 경구 투여했을 때, 세균의 내독소인 리포폴리사카라이드(LPS; lipopolysaccharide)에 의해 유발된 쥐 취사율을 저해하는 효능이 동량의 인산용액만을 경구투여한 대조군에 대하여 우수함을 알 수 있었다.As can be seen in Figures 1 and 2, when oral administration of buckwheat fraction extract and buckwheat husk fraction extract to the rat, the mouse cooking rate caused by bacteria endotoxin lipopolysaccharide (LPS; lipopolysaccharide) The inhibitory effect was superior to the control group orally administered the same amount of phosphate solution.
도 3 내지 도 4를 통하여, 메밀 분획추출물과 메밀껍질 분획추출물은 피부염증 유발물질인 티피에이(TPA; 12-ο-tetradecanoylphorbol-13-acetate)에 의해 유발된 쥐의 귀 염증에 대한 저해 효능을 나타내었으며, 도 5에서 보듯이 종래의 항염증 물질로 알려진 녹차의 에피갈로카테킨갈레이트와 비교하여 귀 염증 저해율이 유사함을 확인할 수 있었다.3 through 4, the buckwheat fraction extract and the buckwheat husk fraction extract have inhibitory effects on ear inflammation in rats induced by dermal inflammation causing TPA (12- ο- tetradecanoylphorbol-13-acetate). As shown in FIG. 5, the ear inflammation inhibition rate was similar to that of epigallocatechin gallate of green tea, which is known as a conventional anti-inflammatory substance.
본 발명에 따르면, 메밀, 메밀껍질, 및 이들의 혼합물로 이루어진 군으로부터 선택된 물질의 추출물은 세균이 분비하는 내독소 및 외부 염증 유발 물질에 의해 발생하는 염증을 효과적으로 억제할 수 있다. 또한 상기 추출물은 식품 등급으로 사용할 수 있어, 독성을 제거하기 위한 별도의 정제 과정 없이 안전하게 섭취할 수 있으므로, 항염증 활성을 가지는, 메밀, 메밀껍질, 및 이들의 혼합물로 이루어진 군으로부터 선택된 물질의 추출물을 식품에 첨가하여 섭취하게 되면 항염증 효능을 얻을 수 있다. 특히 버려지고 있는 막대한 양의 메밀껍질을 재활용함으로써 경제성을 향상시킬 수 있다.According to the present invention, an extract of a material selected from the group consisting of buckwheat, buckwheat husk, and mixtures thereof can effectively suppress inflammation caused by endotoxins and external inflammation causing substances secreted by bacteria. In addition, the extract can be used in food grade, so that it can be safely ingested without a separate purification process to remove the toxicity, so having an anti-inflammatory activity, an extract of a material selected from the group consisting of buckwheat, buckwheat bark, and mixtures thereof When added to foods can be obtained anti-inflammatory benefits. In particular, the economy can be improved by recycling the enormous amount of buckwheat husk that is being discarded.
이하, 본 발명의 이해를 돕기 위하여 바람직한 실시예를 제시하나, 하기 실시예는 본 발명을 예시하는 것일 뿐 본 발명의 범위가 하기 실시예에 한정되는 것은 아니다.Hereinafter, preferred examples are provided to help understanding of the present invention, but the following examples are merely to illustrate the present invention, and the scope of the present invention is not limited to the following examples.
[실시예]EXAMPLE
실시예 1. 메밀 분획추출물의 제조Example 1 Preparation of Buckwheat Fraction Extract
건조된 메밀 1 중량부에 50 % 에탄올(Duksan, Korea) 수용액을 약 6 배정도 첨가하여 실온에서 교반기를 이용하여 6 시간 동안 환류추출하였다. 이를 8,000rpm, 30 분간 원심분리(Vision, Korea)하여 얻어진 상등액을 모으고, 잔류물은 동일한 방법으로 1 회 반복추출하였다. 이렇게 얻어진 추출물을 여과지(whatmann 41)로 여과시킨 후, 냉동 건조하여 메밀 용매추출물(이하, "메밀 용매추출물"이라 함)을 얻었다.50% ethanol (Duksan, Korea) aqueous solution was added about 6 times to 1 part of dried buckwheat and refluxed for 6 hours using a stirrer at room temperature. The supernatant obtained by centrifugation (Vision, Korea) for 30 minutes at 8,000 rpm, was collected, and the residue was repeatedly extracted once in the same manner. The extract thus obtained was filtered with filter paper (whatmann 41), and then freeze-dried to obtain a buckwheat solvent extract (hereinafter referred to as "buckwheat solvent extract").
상기 얻어진 메밀 용매추출물을 흡착 칼럼크로마토그래피를 수행하여 메밀 용매추출물의 분획추출물(이하, "메밀 분획추출물"이라 함)을 제조하였다. 구체적으로, 상기 메밀 용매추출물을 소수성 충진제인 XAD-4(Sigma, USA) 또는 HP-20(Mitsbish, Japan)에 흡착시킨 후, 20 % 에탄올을 흘려서 단백질이나 당과 같은 영양성분을 포함하는 분획을 제거하였다. 여기서 남은 분획에 다시 40 % 에탄올을 흘려서 메밀 분획추출물을 얻었다.The obtained buckwheat solvent extract was subjected to adsorption column chromatography to prepare a fraction extract of buckwheat solvent extract (hereinafter referred to as "buckwheat fraction extract"). Specifically, the buckwheat solvent extract is adsorbed onto XAD-4 (Sigma, USA) or HP-20 (Mitsbish, Japan), which is a hydrophobic filler, and 20% ethanol is poured to fractions containing nutrients such as proteins or sugars. Removed. 40% ethanol was poured again into the remaining fractions to obtain a buckwheat fraction extract.
실시예 2. 메밀껍질 분획추출물의 제조Example 2 Preparation of Buckwheat Peel Fraction Extract
메밀껍질을 출발물질로 사용하는 것을 제외하고는, 상기 실시예 1과 동일한 방법을 수행하여 메밀껍질의 용매추출물(이하, "메밀껍질의 용매추출물"이라 함)을 얻고, 메밀껍질의 용매추출물로부터 흡착 칼럼 크로마토그래피에 의해 메밀 껍질의 분획추출물(이하, 메밀껍질의 분획추출물)을 제조하였다.Except for using buckwheat husk as a starting material, the same method as in Example 1 was carried out to obtain a solvent extract of buckwheat husk (hereinafter referred to as "solvent extract of buckwheat husk"), and from the solvent extract of buckwheat husk Fraction extract of buckwheat husk (hereinafter, fraction extract of buckwheat husk) was prepared by adsorption column chromatography.
실시예 3. 세균의 내독소에 의해 발생되는 염증의 저해 효과Example 3 Inhibitory Effect of Inflammation Caused by Bacterial Endotoxin
상기 실시예 1과 실시예 2에서 얻은 메밀 분획추출물과 메밀껍질 분획추출물의 세균의 내독소에 의해 발생하는 염증에 대한 억제활성을 측정하였다. 이를 측정하는 방법으로는 하기 공지의 방법(Yang et al., J. Nutr., 128: 2334-2340, 1998)에 따라 실시하였다.The inhibitory activity against inflammation caused by endotoxin of bacteria of the buckwheat fraction extract and the buckwheat husk fraction extract obtained in Examples 1 and 2 was measured. As a method for measuring this, it was carried out according to the following known method (Yang et al., J. Nutr., 128: 2334-2340, 1998).
먼저 25∼30 g의 BALB/C 쥐를 한 군당 25 마리씩 준비하여 실험 전에 12 시간 절식시킨 후, 실시예 1과 실시예 2에서 얻은 메밀 분획추출물과 메밀껍질 분획추출물을 1 g/㎏ 농도로 쥐에 경구투여하였다. 반면, 대조군으로는 동량의 인산용액만을 경구투여시켰다. 30 분 후에 자이라진 하이드로클로라이드(xylazine hydrochloride)로 마취시킨 후, 다시 5 분 후에 40 ㎎/㎏의 리포폴리사카라이드(lipopolysaccharide)를 복강내로 투여하였다. 30 시간까지 매 2 시간마다 생존율을 측정하였고, 대조군에 대한 생존수의 차이에 따라 항염증 정도를 측정하였다.First, 25-30 g of BALB / C mice were prepared in 25 groups per group and fasted for 12 hours before the experiment. Then, the buckwheat fraction extract and the buckwheat shell fraction extracts obtained in Examples 1 and 2 were treated at 1 g / kg. Orally administered to. On the other hand, only the same amount of phosphate solution was orally administered as a control. After 30 minutes of anesthesia with xylazine hydrochloride, 40 mg / kg lipopolysaccharide was administered intraperitoneally after 5 minutes. Survival was measured every 2 hours until 30 hours, and the degree of anti-inflammatory was measured according to the difference in survival numbers for the control group.
실시예 1과 실시예 2에서 얻은 메밀 분획추출물과 메밀껍질 분획추출물이 각각 세균의 내독소이면서 염증유발 물질인 리포폴리사카라이드에 의해 발생하는 쥐의 사망률에 대해 저해 효능을 가짐을 도 1과 도 2에 나타내었다.The buckwheat fraction extract and the buckwheat husk fraction extract obtained in Examples 1 and 2 have inhibitory effects on the mortality rate of rats caused by lipopolysaccharide, a bacterial endotoxin and an inflammatory substance, respectively. 2 is shown.
도 1은 실시예 1의 메밀 분획추출물을 쥐에 경구 투여했을 때, 메밀 분획추출물이 리포폴리사카라이드에 의해 유발된 쥐 치사율을 저해하는 것을 나타내는 것이다. 도 2는 실시예 2의 메밀껍질 분획추출물을 쥐에 경구 투여했을 때, 메밀껍질 분획추출물이 리포폴리사카라이드에 의해 유발된 쥐 치사율을 저해하는 것을 나타내는 것이다.1 shows that when the buckwheat fraction extract of Example 1 is orally administered to rats, the buckwheat fraction extract inhibits rat mortality caused by lipopolysaccharide. Figure 2 shows that when the buckwheat husk fraction extract of Example 2 orally administered to the rat, the buckwheat husk fraction extract inhibits rat mortality caused by lipopolysaccharide.
도 1 및 도 2를 통하여 실시예 1과 실시예 2에서 얻은 메밀 분획추출물과 메밀껍질 분획추출물은 각각 0.5 g/㎏ 농도로 쥐에 경구 투여한 후, 30 시간에서 대조군과 비교하여 각각 52 %와 40 %의 치사율 감소가 관찰되었으며, 12 시간에서는 각각 44 %와 44 %의 치사율 감소 효과를 나타내었다.The buckwheat fraction extract and the buckwheat husk fraction extract obtained in Examples 1 and 2 through FIGS. 1 and 2 were orally administered to rats at a concentration of 0.5 g / kg, respectively, and 52% and 30%, respectively, compared to the control at 30 hours. A 40% mortality reduction was observed, and at 12 hours, 44% and 44% mortality reduction effects, respectively.
실시예 4. TPA에 의해 유발되는 염증의 저해 효과Example 4 Inhibitory Effect of Inflammation Induced by TPA
상기 실시예 1과 실시예 2에서 얻은 메밀 분획추출물과 메밀껍질 분획추출물의 티피에이(TPA; 12-ο-tetradecanoylphorbol-13-acetate)에 의해 발생하는 염증에 대한 억제활성을 측정하였다. 이를 측정하는 방법으로는 하기 공지의 방법(Romay C., et al., Inflamm. Res. 47: 334-338, 1998)에 따라 실시하였다.The inhibitory activity against the inflammation caused by the buckwheat fraction extract and the buckwheat husk fraction extract obtained in Examples 1 and 2 by TPA (12- ο- tetradecanoylphorbol-13-acetate) was measured. As a method for measuring this, it was carried out according to the following known method (Romay C., et al., Inflamm. Res. 47: 334-338, 1998).
먼저, 25∼30 g의 BALB/C 쥐를 한 군당 8 마리씩 준비하여 실험 전에 12 시간 절식시킨 후, 상기 실시예 1과 실시예 2에서 얻은 메밀 분획추출물과 메밀껍질 분획추출물을 0.01 g/㎏, 0.1 g/㎏, 0.5 g/㎏, 1.0 g/㎏의 각각의 농도로 경구투여시켰다. 30 분 후에 자이라진 하이드로클로라이드(xylazine hydrochloride)로 마취시킨 후, 다시 5 분 후에 TPA를 각 귀당 25 ㎍씩 양쪽 귀에 도포하였다. 5 시간 후에 오른쪽과 왼쪽 귀를 6 ㎜ 펀치(punch)로 잘라내어 무게를 측정하였다. 항염증 억제율은 메밀 분획추출물과 메밀껍질 분획추출물과 티피에이를 함께 처리한 군의 무게 증가량의 감소율을 이용하였다. 대조군으로는 동량의 티피에이만을 첨가한 쥐의 무게 증가량을 사용하였다. 모든 그림은 평균값으로 나타냈으며, 통계적 유의성은 유의수준 * P<0.05, ** P<0.01에서 two-tailed Dunnett's t-test를 따라서 ANOVA 법에 의해 검정하였다.First, 25 to 30 g of BALB / C mice were prepared per group and fasted for 12 hours before the experiment, and then 0.01 g / kg of the buckwheat fraction extract and the buckwheat shell fraction extract obtained in Examples 1 and 2, Oral administration was performed at the respective concentrations of 0.1 g / kg, 0.5 g / kg and 1.0 g / kg. After 30 minutes of anesthesia with xylazine hydrochloride, after 5 minutes, TPA was applied to both ears at 25 μg per ear. After 5 hours the right and left ears were cut out with a 6 mm punch and weighed. Anti-inflammatory inhibition rate was used to reduce the weight increase of the buckwheat fraction extract, buckwheat husk fraction extract and TPI. As a control, an increase in the weight of rats in which only the same amount of TPE was added was used. All plots were averaged and statistical significance was tested by ANOVA method according to two-tailed Dunnett's t-test at significance level * P <0.05, ** P <0.01.
실시예 1과 실시예 2에서 얻은 메밀 분획추출물과 메밀껍질 분획추출물이 염증유발 물질인 티피에이에 의해 발생하는 염증을 저해하는 효능을 도 3과 도 4에 나타내었다.The buckwheat fraction extract and the buckwheat husk fraction extract obtained in Examples 1 and 2 are shown in Figure 3 and 4 the effect of inhibiting the inflammation caused by the inflammatory TIP.
도 3은 실시예 1의 메밀 분획추출물을 쥐에 경구 투여했을 때, 메밀 분획추출물이 피부염증 유발 물질인 티피에이에 의해 유발된 쥐의 귀 염증을 억제함을 나타내는 것이다. 도 4는 실시예 2의 메밀껍질 분획추출물을 쥐에 경구 투여했을 때, 메밀껍질 분획추출물이 티피에이에 의해 유발된 쥐의 귀 염증을 억제함을 나타내는 것이다.Figure 3 shows that when the buckwheat fraction extract of Example 1 orally administered to the rat, the buckwheat fraction extract inhibits ear inflammation of the rat caused by TPI, a dermatitis-inducing substance. Figure 4 shows that when the buckwheat husk fraction extract of Example 2 orally administered to the rat, the buckwheat husk fraction extract inhibits ear inflammation in rats induced by Typhi.
도 3 및 도 4를 통하여 본 발명의 실시예 1과 실시예 2에서 얻은 메밀 분획추출물과 메밀껍질 분획추출물은 각각 0.1 g/㎏ 농도로 쥐에 경구 투여시 각각 61 %와 59 %의 염증 저해율을 나타냈으며, 0.5 g/㎏ 농도로 경구 투여시에는 각각 69 %와 73 %의 염증 저해율을 나타냄으로써 유사한 저해 효능을 나타내었다. 또한, 이러한 항염증 효능은 메밀 분획추출물과 메밀껍질 분획추출물의 농도에 비례하여 증가함을 알 수 있다.The buckwheat fraction extract and the buckwheat husk fraction extract obtained in Examples 1 and 2 of the present invention through Figures 3 and 4, respectively, when the oral administration to rats at the concentration of 0.1 g / kg, respectively, 61% and 59% Oral administration at a concentration of 0.5 g / kg showed a similar inhibitory effect, showing an inhibition rate of 69% and 73%, respectively. In addition, this anti-inflammatory effect is found to increase in proportion to the concentration of buckwheat fraction extract and buckwheat shell fraction extract.
비교예 1Comparative Example 1
상기 실시예 1에서 얻은 메밀 분획추출물 0.3 g/㎏, 상기 실시예 2에서 얻은 메밀껍질 분획추출물 0.3 g/㎏, 및 항염증 물질로 잘 알려진 녹차의 에피갈로카테킨갈레이트(EGCG; epigallocatechingallte) 0.1 g/㎏의 농도로 경구투여한 후, 상기 실시예 4와 동일한 방법을 이용하여 티피에이에 의해 발생하는 염증에 대한 억제 효능을 측정하고, 그 결과를 도 5에 나타내었다.0.3 g / kg of buckwheat fraction extract obtained in Example 1, 0.3 g / kg of buckwheat hull fraction extract obtained in Example 2, and epigallocatechingallate (EGCG) 0.1 of green tea, which is well known as an anti-inflammatory substance After oral administration at a concentration of g / kg, by using the same method as in Example 4 was measured the inhibitory effect on the inflammation caused by TI. The results are shown in FIG.
실시예 5: 독성 시험Example 5: Toxicity Test
본 발명의 메밀 분획추출물과 메밀껍질의 분획추출물에 대하여 독성실험을 다음과 같이 수행하였다. 구체적으로 상기 분획추출물 각각을 디메틸설폭사이드(DMSO; dimethylsulfoxide)에 용해하고 물로 희석한 후 이를 마우스(군당 10 마리)에 각각 1 g/㎏을 투여한 다음, 7 일간 관찰하였으나 사망하는 쥐는 없었다.Toxicity test was performed on the buckwheat fraction extract and the buckwheat husk fraction extract of the present invention as follows. Specifically, each of the fraction extracts was dissolved in dimethylsulfoxide (DMSO; dimethylsulfoxide), diluted with water, and then administered to the mice (10 mice per group), respectively, 1 g / kg, and observed for 7 days, but there was no death.
상기에서 살펴본 바와 같이, 본 발명의 메밀, 메밀껍질, 및 이들의 혼합물로 이루어진 군에서 선택된 물질의 용매추출물과 분획추출물은 항염증 활성을 가지며, 특히 세균이 분비하는 내독소 및 외부 염증 유발 물질에 의해 발생하는 염증을 효과적으로 억제할 수 있다. 또한 상기 추출물은 식품 등급으로 사용할 수 있어, 독성을 제거하기 위한 별도의 정제 과정 없이 안전하게 섭취할 수 있으므로, 이를 식품에 첨가하여 섭취하게 되면 항염증 효능을 얻을 수 있다. 특히, 버려지고 있는 막대한 양의 메밀껍질을 재활용함으로써 경제성을 향상시킬 수 있다.As described above, the solvent extract and fraction extract of the material selected from the group consisting of buckwheat, buckwheat bark, and mixtures thereof of the present invention have anti-inflammatory activity, in particular to endotoxins and external inflammation causing substances secreted by bacteria. Inflammation caused by this can be effectively suppressed. In addition, the extract can be used as a food grade, so that it can be safely ingested without a separate purification process to remove toxicity, when added to the food can be obtained anti-inflammatory effect. In particular, the economic efficiency can be improved by recycling the enormous amount of buckwheat husk that is discarded.
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2001-0060247A KR100441565B1 (en) | 2001-09-27 | 2001-09-27 | Extracts of buckwheat and/or buchwheat chaff with anti-inflammatory effects and food composition comprising of the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2001-0060247A KR100441565B1 (en) | 2001-09-27 | 2001-09-27 | Extracts of buckwheat and/or buchwheat chaff with anti-inflammatory effects and food composition comprising of the same |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2004-0018778A Division KR100441567B1 (en) | 2004-03-19 | 2004-03-19 | Extracts of buckwheat and/or buchwheat chaff with anti-inflammatory effects and pharmaceutical composition comprising the same |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20030028234A true KR20030028234A (en) | 2003-04-08 |
KR100441565B1 KR100441565B1 (en) | 2004-07-23 |
Family
ID=29562667
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2001-0060247A KR100441565B1 (en) | 2001-09-27 | 2001-09-27 | Extracts of buckwheat and/or buchwheat chaff with anti-inflammatory effects and food composition comprising of the same |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100441565B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107898829A (en) * | 2017-09-26 | 2018-04-13 | 吉林农业大学 | Advanced glycation end products decomposition agent |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100845243B1 (en) * | 2006-11-10 | 2008-07-10 | 주식회사 케이씨에프코리아 | Composition for anti-helicobacter pylori containing buck wheat extract |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100217884B1 (en) * | 1996-12-18 | 1999-09-01 | 김동태 | The buckwheat sprout and the method for cultivating it |
KR100509119B1 (en) * | 1999-07-16 | 2005-08-18 | 주식회사 엘지생활건강 | Medicine comprising procyanidine as an effective agent |
KR20010100254A (en) * | 2000-03-30 | 2001-11-14 | 더블유. 유 병 | Preparing method for vitamin C rich noodle foods |
KR100329010B1 (en) * | 2000-10-23 | 2002-03-20 | 강창환 | The composites of raw-type tea containing propolis extract powder |
KR100336646B1 (en) * | 2000-11-23 | 2002-05-16 | 강창환 | The composites of raw-type tea containing arabinoxylane |
-
2001
- 2001-09-27 KR KR10-2001-0060247A patent/KR100441565B1/en active IP Right Grant
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107898829A (en) * | 2017-09-26 | 2018-04-13 | 吉林农业大学 | Advanced glycation end products decomposition agent |
Also Published As
Publication number | Publication date |
---|---|
KR100441565B1 (en) | 2004-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6387467B2 (en) | Mangosteen extract or composition for preventing or ameliorating periodontal disease comprising alpha and gamma mangosteen as active ingredients | |
JP2002179586A (en) | Lipase inhibitor | |
JP2005060334A (en) | Anti-obesity agent having lipase inhibiting activity and antioxidation activity | |
KR101760512B1 (en) | Compositions comprising mixed herbal extracts for preventing, treating or improving chronic inflammatory diseases | |
JP4432069B2 (en) | Obesity inhibitor | |
KR102519649B1 (en) | Composition for the prevention or treatment of prostate-related disease comprising Rhodiola sachalinensis root extract containing kaempferol and epicatechin gallate | |
JP5309292B2 (en) | Lipase inhibitor | |
JP2006160710A (en) | Composition for preventing/treating diabetes and health food containing the active ingredient thereof | |
KR100441565B1 (en) | Extracts of buckwheat and/or buchwheat chaff with anti-inflammatory effects and food composition comprising of the same | |
KR100441567B1 (en) | Extracts of buckwheat and/or buchwheat chaff with anti-inflammatory effects and pharmaceutical composition comprising the same | |
JP3549997B2 (en) | Food composition and pharmaceutical composition having lipase inhibitory effect | |
JP5976271B2 (en) | Lipase inhibitor and cosmetics, food / beverage composition and pharmaceutical composition containing the same | |
KR20180082921A (en) | Composition for preventing or treating gastritis or peptic ulcer | |
KR20180065419A (en) | Composition for anti-inflammation with nipa fruticans wurmb | |
KR101332824B1 (en) | Pharmaceutical Compositions for Preventing or Treating Arthritis Comprising Euphorbia ebracteolata Extracts | |
KR20220069727A (en) | Antibacterial composition containing starfish extract and cinnamon extract as active ingredients | |
JP3142192B2 (en) | Blood lipid improving agent and composition containing the same | |
JP2006160625A (en) | Water-soluble extract derived from bee larva having protease inhibitory action, method for producing the same, and product containing the same | |
JP2011079752A (en) | Pancreatic lipase inhibitor, food and beverage composition containing the same and pharmaceutical composition | |
JP3183754B2 (en) | Arteriosclerosis inhibitor and composition containing the same | |
KR100836711B1 (en) | Pharmaceutical composition containing arazyme for the prevention of liver dysfunction | |
JPWO2005056031A1 (en) | Lipase inhibitor | |
WO2016182147A1 (en) | Composition containing solanum carolinense extract as active ingredient for preventing or treating periodontal disease | |
KR100460104B1 (en) | Drug for treatment contact dermatitis and digestive system inflammation containing cacao bean or husk fraction extract | |
KR100441566B1 (en) | Extracts of buckwheat and/or buchwheat chaff with inhibitory effects on hepatocarcinogenesis and pharmaceutical composition comprising the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
A107 | Divisional application of patent | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130702 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20140702 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20151224 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20160204 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20170626 Year of fee payment: 14 |
|
FPAY | Annual fee payment |
Payment date: 20180620 Year of fee payment: 15 |
|
FPAY | Annual fee payment |
Payment date: 20190625 Year of fee payment: 16 |